SECO
SECO
March 01, 2018
5 min watch
Save

VIDEO: Drugs, devices bring ‘new era’ of glaucoma care

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ATLANTA – “A new era of glaucoma management has arrived,” J. James Thimons, OD, said here at SECO. Thimons discussed how Rhopressa (netarsudil ophthalmic solution 0.02%, Aerie Pharmaceuticals) relaxes the trabeculum and may provide some form of trabecular regeneration. He said Vyzulta (latanoprostene bunod ophthalmic solution 0.024%, Bausch + Lomb) has an additive effect to latanoprost acid by increasing vascular permeability and flow in and around the trabecular meshwork.

Thimons explained how these two new drugs, as well as new micro-invasive glaucoma surgery procedures, fit into the glaucoma patient care regimen.